Table 2.
Summarized performance characteristics of 4 SARS-CoV-2 IgG LFIAs.
| Assay | Sensitivity≥14 d from onseta (95% CI; BTNX & ACON, n = 95; SD, n = 50) | Agreement with Abbott SARS-CoV-2 IgG assay (95% CI; BTNX & ACON, n = 81; SD, n = 43) | Specificity ≥14 d from onset (95% CI; n = 105)) |
|---|---|---|---|
| Rapid Response™ COVID-19 Test Cassette (BTNX Inc.) Kit 1 | 95% (88–98%) | 99% (93–100%) | 98% (93–100%) |
| Rapid Response™ COVID-19 Test Cassette (BTNX Inc.) Kit 2 | 91% (83–96%) | 94% (86–98%) | 100% (97–100%) |
| SARS-COV-2 IgG/IgM Rapid Test (ACON Laboratories) | 95% (88–98%) | 99% (93–100%) | 98% (93–100%) |
| Standard Q COVID-19 IgM/IgG Duo (SD BIOSENSOR) | 92% (81–98%) | 100% (92–100%) | 100% (97–100%) |
a
Where a “true positive” is a specimen collected ≥14 days after symptom onset from an RT-PCR–confirmed COVID-19 case.